[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Norfolk and Norwich University Hospitals NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":224},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,83,110,145,174,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100363625","measurement-of-nt-probnp-to-predict-outcomes-in-surgery-100363625",false,"NCT04014647","Measurement Of NT-proBNP to Predict Outcomes in Surgery","Peri-operative Measurement of NT-proBNP to Predict Outcomes in Patients Undergoing Elective Vascular Surgery","MOBOS","Inclusion Criteria:\n\n* Patients who are equal to or over 18 years old\n* Patients scheduled to undergo elective surgery for the following procedures:\n* Infrainguinal arterial reconstruction\n* Aortic aneurysm\n* Aorto-bifemoral bypass \u002F or aortic endarterectomy\n* Femoro-popliteal bypass\n* Femoro-distal bypass\n* Femoral endarterectomy\n* Femoro-femoral crossover\n* Axillo-femoral bypass\n* Elective carotid surgery\n* Patients having either general or regional anaesthesia for their surgery\n\nExclusion Criteria:-\n\n* Patients undergoing emergency surgery\n* Those who are unable or unwilling to give informed consent\n* Patients with unstable coronary syndromes (acute or recent MI with evidence of important ischemic risk by clinical symptoms or stress testing or unstable or severe angina pectoris)\n* Patients with decompensated heart failure (new onset shortness of breath and rales together with echocardiographic evidence of cardiac dysfunction or deterioration of chronic heart failure despite heart failure therapy)\n* Patients with chronic atrial fibrillation","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","The team is investigating whether N-terminal pro B-type natriuretic peptide (NT-proBNP) and other cardiac markers are useful for predicting outcomes for patients undergoing vascular surgery. By measuring NT-proBNP before and after surgery, the investigators may be able to determine which patients are at risk of an adverse outcome, such as a heart attack or death.",[25],"Vascular Surgical Procedure",[25,27,28,29,30,31,32],"Pro-brain natriuretic peptide (1-76)","Natriuretic Peptide, Brain","Troponin I","Galectin 3","Biomarkers","Risk","RECRUITING","2026-06-05",{"date":36,"type":37},"2026-06-08","ACTUAL",{"date":39,"type":37},"2019-09-05",{"date":41,"type":21},"2029-09-05",{"name":43,"class":44},"Norfolk and Norwich University Hospitals NHS Foundation Trust","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100638485","the-ok-daily-study-100638485","NCT07620236","The OK Daily Study","Oral Vitamin K2 (Menaquinone-7; MK-7) Supplementation and Effect on Vitamin K Status of Breastfed Term Infants in Early Infancy; a Four-cohort Prospective, Part-randomised, Part-blinded Study.","Inclusion Criteria:\n\n* Infants, and mothers of infants, born ≥37 weeks gestational age\n* Standard dose of intramuscular (IM) vitamin K prophylaxis given to the neonate following birth\n* For breastfeeding mothers: the mother intends to exclusively\u002Fpredominantly breastfeed their baby for at least 2 months\n\nExclusion Criteria:\n\n* Inability or refusal to provide informed consent\n* Inability to adhere to or comply with study procedures\n* Babies who meet the inclusion gestation but would otherwise, as part of routine neonatal care, be provided with daily vitamin K drops (i.e. NeoKay drops) at discharge\n* IM vitamin K prophylaxis not received at birth (parents declined vitamin K prophylaxis or parents chose for neonate to receive an oral course of vitamin K prophylaxis instead)\n* Evidence of conjugated hyperbilirubinaemia (these babies are at higher risk of VKDB)\n* Mothers, and babies born to mothers, who are taking any medication that could affect or antagonise vitamin K metabolism (i.e. warfarin, the anti-epileptic drugs phenytoin or carbamazepine, and cephalosporin, rifampicin and isoniazid antimicrobials)",true,"7 Days",{"count":56,"type":21},134,"INTERVENTIONAL",[59],"NA","The OK Daily Study is a multi-centred, part-randomised, part blinded, four cohort study. We are exploring daily dietary supplementation with vitamin K2, specifically menaquinone-7 (MK-7), given to breastfed infants or breastfeeding mothers to see whether this improves the incidence of biochemical vitamin K deficiency in the infants at 2 months postnatal age.\n\nThe overall aims are:\n\n* To compare infant MK-7 supplementation with placebo\n* To compare maternal MK-7 supplementation with placebo\n* To compare infant MK-7 supplementation and maternal MK-7 supplementation\n* To compare infant MK-7 supplementation with vitamin K1 supplementation via infant formula milk.\n\nOnce recruited, mother and infant pairs will be grouped initially based on the families' feeding choice. Breastfed infants will then be randomised 2:1 to the infant supplementation or maternal supplementation group. Within the infant supplementation group, infants will either receive MK-7 with vitamin D or a placebo containing vitamin D.\n\nFollow up will occur at 2 months postnatal age (range 2-3 months postnatal age), where bloods and breastmilk samples will be collected to assess the infant and maternal vitamin K status.",[62,63],"Infant Vitamin K Status","Vitamin K Deficiency Bleeding",[65,66,67,68,69,70,71,72,73],"Oral vitamin K","vitamin K1 vs K2","menaquinone-7 (MK-7)","vitamin K status","PIVKA-II","undercarboxylated\u002Fcarboxylated osteocalcin ratio","neonate","infant","breastfeeding","NOT_YET_RECRUITING","2026-05-27",{"date":77,"type":37},"2026-06-02",{"date":79,"type":21},"2026-08-01",{"date":81,"type":21},"2028-08-01",{"name":43,"class":44},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":57,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":45},"100595026","influence-of-perfluorocarbon-liquid-liquid-during-pars-plana-vitrectomy-on-retinal-vessel-displacement-in-primary-macula-involving-rhegmatogenous-retinal-detachment-100595026","NCT07027098","Influence of Perfluorocarbon Liquid (LIQUID) During Pars Plana Vitrectomy on Retinal Vessel Displacement in Primary Macula-involving Rhegmatogenous Retinal Detachment","Retinal Displacement After Pars Plana Vitrectomy for Macula Involving Retinal Detachment: A Randomised Prospective Study Evaluating the Role of Intraoperative Perfluorocarbon Liquids","LIQUID","Inclusion Criteria:\n\n* 18 years of age, or older.\n* Diagnosis of primary MIRD with posterior vitreous detachment, and fovea off (confirmed with OCT)\n* Surgeons' decision that the patient is eligible for using gas as postoperative tamponade.\n* The surgeon is confident to proceed with surgery with or without the use of intraoperative PFCL\n\nExclusion Criteria:\n\n* Previous RRD and\u002For RRD surgery in the study eye\n* Decision to use adjunct scleral buckle\n* Decision to use silicone oil as tamponade\n* Retinal detachment with macula on\n* Patients with other retinal pathologies causing permanent structural changes to the retina in the study eye, such as diabetic retinopathy (assessed above background, or any diabetic maculopathy), previous vascular occlusion (artery or vein occlusion), macula dystrophy, among others\n* Previous vitreoretinal surgery in the study eye\n* Inability to come for follow ups up to 3 months\n* Inability to take FAF and OCT imaging due to neck stiffness or other medical issue\n* Mental incapacity\n* Patient is unwilling or unable to follow or comply with all study related procedures or to sign informed consent form.\n* Contraindications for PFCL\n* Previous enrollment in a clinical trial involving retinal diseases and\u002For treatments\n* Media opacity leading to poor quality retinal images (not including post operative significant cataract. See section 7.11)\n* Patient inability to posture following surgery",{"count":92,"type":21},292,[59],"Rhegmatogenous retinal detachment (RRD) is an acute, sight threatening condition, with an incidence of approximately 10 per 100,000 people. Surgical interventions for treating RRD include pars plana vitrectomy (PPV), which currently represents the main adopted surgical choice. Main outcomes of successful RRD surgery have mainly been represented by anatomical retinal reattachment and best-corrected visual acuity (BCVA). Despite successful surgery, patients with mac-off RRD often report postoperative visual complaints of distortion such as metamorphopsia and scotomas in their central visual field, with great variability.\n\nMajor advances in retinal imaging including wide-field optical coherence tomography (OCT) and fundus autofluorescence (FAF) allowed to investigate morphological changes after RRD surgery. The concept of retinal displacement - where the retina has reattached but the exact location has shifted, as evidenced by retinal vessel printing shown on post operative retinal imaging.\n\nPostoperative retinal displacement has been observed to occur with different frequency in relationship to variables including postoperative tamponade, surgical technique, and intraoperative use of perfluorocarbon liquids (PFCL). The investigators hope to formally study the impact of intraoperative use of PFCL, which is used as an aid during surgery to help flatten and position the retina, on retinal displacement. This will help us better understand the impact of this tool on outcomes both objectively through retinal imaging, and subjectively through visual outcomes including visual acuity and measures of distortion and other visual disturbances.",[96],"Retinal Displacement After Retinal Detachment Surgery",[98,99,100,101],"Retinal displacement","retinal detachment","Heavy liquid","perfluorocarbon liquids","2026-04-09",{"date":104,"type":37},"2026-04-14",{"date":106,"type":37},"2025-10-28",{"date":108,"type":21},"2027-10-01",{"name":43,"class":44},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":57,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100436594","phase-3-treating-people-with-idiopathic-pulmonary-fibrosis-with-the-addition-of-lansoprazole-100436594","NCT04965298","Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole","The Effectiveness and Risks of Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole: a Randomised Placebo-controlled Multi-centre Clinical Trial","TIPAL","Inclusion Criteria:\n\n1. Male or female, aged greater than or equal to 40 years.\n2. A diagnosis of Idiopathic Pulmonary Fibrosis (IPF) based on local or regional multi-disciplinary consensus according to the latest international guidelines (50).\n3. Patients may be receiving licensed anti-fibrotic medication (for at least 4 weeks prior to randomisation with no planned amendments for at least 4 weeks post-randomisation).\n4. Able to provide informed consent.\n\nAdditional Inclusion Criteria for cough count sub-study:\n\n1\\. Pre-existing diagnosis of persistent cough (defined as troublesome for more than 8 weeks prior to study enrolment).\n\nExclusion Criteria:\n\n1. Patients unable to comply with study assessments including the ability to complete reliable spirometry assessments.\n2. Concomitant use of a proton pump inhibitor (PPI) or prokinetic drugs (cisapride, domperidone, metoclopramide, erythromycin, prucalopride etc.) within 2 weeks prior to randomisation.\n3. Patients with a self-reported respiratory tract infection within 4 weeks of screening (defined as two or more of: increased cough, sputum or breathlessness and requiring antimicrobial therapy).\n4. Significant co-existing respiratory disease (defined as a respiratory condition that exhibits a clinically relevant effect on respiratory symptoms and disease progression as determined by the PI). The presence of traction bronchiectasis is permitted.\n5. Patients with an FEV1\u002FFVC\\\u003C0.7.\n6. Significant medical, surgical or psychiatric disease that in the opinion of the patient's attending physician would affect subject safety or influence the study outcomes including liver failure (e.g. serum transaminase \\> 2 x upper limit of normal (ULN), Bilirubin \\> 1.5 x ULN (unless the patient has Gilbert's Syndrome) and chronic kidney disease (CKD) greater than stage 3 , erosive oesophagitis, Barrett's oesophagus or any condition requiring lifelong proton pump inhibitor use.\n7. Known allergy to proton pump inhibitors or the contents of placebo.\n8. Concomitant use of atazanavir, ketoconazole, itraconazole, tacrolimus, methotrexate, fluvoxamine (see section 6.4.5).\n9. Females who are of childbearing potential or lactating. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n10. Receipt of another investigational drug or biological agent associated with another clinical trial within the 4 weeks prior to TIPAL study enrolment or 5 times the drug half-life, whichever is the longer.\n11. Receiving long-term oxygen therapy.\n12. Patients with hypomagnesemia (defined as magnesium ≤0.6 mmol\u002FL).","40 Years",{"count":120,"type":21},298,[122],"PHASE3","IPF is a progressive scarring lung condition causing coughing and breathlessness. IPF patients often have reflux disease meaning stomach acid may be breathed into the lungs, potentially damaging them. Medicines which stop stomach acid production, proton pump inhibitors (PPIs), can be used to reduce reflux symptoms including heartburn. Some researchers suggest PPIs also reduce IPF progression.\n\nThis research aims to see if IPF progresses slower if treated with PPIs. Based on the results, we will be able to recommend whether or not IPF patients should take PPIs.\n\nThis trial will involve 298 IPF patients from approximately 37 UK hospitals. At the beginning of the study, we will ask patients to start performing weekly breathing tests at home using equipment provided, and ask those with a cough to use a device to count the number of times they cough in 24hours. We will ask them to answer two questions rating their coughing and breathlessness, and complete questionnaires on their coughing, IPF, sleep habits and general condition. People will be given a PPI, called lansoprazole, or dummy tablets, twice per day for 12 months. They will be given a leaflet telling them what to do about reflux symptoms. At the end of the study, we will repeat these tests and analyse the results. We will record any side effects people may get. If people suffer side effects, they can reduce the dose.\n\nPeople taking medicines that interact with PPIs or have other serious medical conditions won't be able to participate. People receiving PPIs will only be able to participate if they can stop taking their medication without their heartburn returning.",[125],"Idiopathic Pulmonary Fibrosis",[127,128,129,130,131,132,133,134,135],"Idiopathic pulmonary fibrosis","IPF","Lansoprazole","Proton pump inhibitors","Cough","FVC","Forced vital capacity","Domiciliary spirometry","Virtual clinical trial","2025-12-15",{"date":138,"type":37},"2025-12-22",{"date":140,"type":37},"2021-06-16",{"date":142,"type":21},"2026-02-28",{"name":43,"class":44},57,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":45},"100605549","the-b-babies-study-an-observational-study-of-group-b-vitamins-in-preterm-infants-100605549","NCT07163962","THE B-BABIES STUDY: An Observational Study of Group B Vitamins in Preterm Infants","Maternal, Milk and Baby Markers of Group B Vitamin Metabolism in (Very) Preterm Infants at the Time of Discharge Home","B-BABIES","Inclusion Criteria:\n\n* Gestational age at birth \\\u003C37 weeks.\n* Admission to one of the participating units.\n* Full enteral milk feeds established by suck\u002Fnasogastric tube\n\nExclusion Criteria:\n\n* Known or suspected chromosomal, genetic or metabolic abnormalities.\n* Major congenital malformations\n* Any intercurrent condition that precludes implementation of standard feeding protocols and requires specialized formulas or changes in standard vitamin supplementation.\n* Any intercurrent condition that will interfere with the interpretation of results (renal impairment and hypothyroidism can lead to elevated tHcy and MMA, for example).","28 Days",{"count":155,"type":21},40,"Infancy may be associated with a risk of micronutrient depletion due to the high demands of rapid growth. This is particularly true when preterm birth occurs, as the period before term exhibits the highest rate of bodily growth across the lifespan. Folate and vitamin B12 are essential in development, and preterm infants may be particularly susceptible to deficiencies. This is the result of a combination of low stores and high requirements for fast growth and rapid red blood cell production in the context of multifactorial anaemia of prematurity. Micronutrient supply, including vitamin B12 and folate, is delivered through nutritional support, in the shape of parenteral nutrition, fortification of human milk of use of artificial formula. Most of this supplementation will be interrupted by the time the infant is getting ready for discharge home. The investigators previously reported high levels of serum folate in preterm infants at the time of discharge home and in early infancy, but there are no contemporary studies investigating the vitamin B12\u002Ffolate status in this population. The investigators aim to investigate the prevalence of vitamin B12 deficiency in preterm infants at the time of discharge home.",[158],"Vitamin B-12 Deficiency",[160,161,162,163,164,165],"Preterm infant","vitamin B12","Folate","Folic acid","Vitamin deficiency","Micronutrition","2025-09-05",{"date":168,"type":37},"2025-09-09",{"date":170,"type":21},"2025-09-01",{"date":172,"type":21},"2026-09-30",{"name":43,"class":44},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100543770","retrospective-study-of-patients-with-acute-presentation-for-asthma-to-an-emergency-department-in-uk-rapae-100543770","NCT06360185","Retrospective Study of Patients with Acute Presentation for Asthma to an Emergency Department in UK (RAPAE)","Retrospective Study Investigating the Clinical Characteristic of Patients with Acute Presentation for Asthma to the A+E Department in a Busy Acute Hospital in England UK in Era of Biological Therapy for Asthma Between Jan 2019 & Jan 2024","RAPAE","Inclusion Criteria:\n\n* All Asthmatics patients who attend Emergency department over 5 years\n\nExclusion Criteria:\n\n* None Asthmatics.","16 Years","99 Years",{"count":185,"type":21},400,"Study team will obtain a list of all patients who have been seen in A+E over the past 6 years with a discharge diagnosis of asthma. Their history will be reviewed from their A+E notes. Team will obtain weight and height from Electronic prescribing tool and will obtain compliance information and past medical history from participant's GP records. Team will use participant's postcode to word out socio economic status quintile using office of national statistics tool. The following information will be taken from hospital documentation and from GP records.",[188],"Asthma Acute","2025-02-25",{"date":191,"type":37},"2025-02-27",{"date":193,"type":21},"2025-12",{"date":195,"type":21},"2027-12-01",{"name":43,"class":44},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":205,"maxAge":183,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100544777","peripheral-arterial-disease-biomarkers-100544777","NCT06373302","Peripheral Arterial Disease Biomarkers","Peripheral Arterial Disease Biomarkers: The Effect of Intervention on Biomarker Levels and Predictors of Restenosis or Deterioration","PADBIRD","Inclusion Criteria:\n\n* Aged \\> 50 years\n* Symptomatic PAD\n* ABPI \\\u003C0.8 or TBPI \\\u003C0.7\n\nExclusion Criteria:\n\n* Aged \\\u003C50 years\n* Current Malignancy\n* Rheumatological Condition\n* Previous surgical or endovascular intervention for PAD\n* ABPI \\>0.8 or TBPI \\>0.7","50 Years",{"count":207,"type":21},100,"The study aims to determine how expression levels of biomarkers for peripheral arterial disease change over time in response to exercise therapy, surgical or endovascular intervention, and whether they can be used to predict disease progression.",[210],"Peripheral Arterial Disease",[212,213,214,215],"Peripheral","Arterial","Disease","Claudication","2024-04-17",{"date":218,"type":37},"2024-04-18",{"date":220,"type":21},"2024-05-01",{"date":222,"type":21},"2026-12-31",{"name":43,"class":44},""]